(-0.06%) 5 203.50 points
(0.02%) 39 004 points
(-0.18%) 18 164 points
(0.27%) $78.69
(-1.64%) $2.16
(-0.15%) $2 327.60
(-0.58%) $27.45
(-0.30%) $962.00
(0.13%) $0.929
(0.32%) $10.86
(0.22%) $0.798
(-1.47%) $90.00
Live Chart Being Loaded With Signals
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC...
Stats | |
---|---|
今日成交量 | 9 870.00 |
平均成交量 | 128 106 |
市值 | 130.35B |
EPS | DKK20.18 ( 2024-05-02 ) |
下一个收益日期 | ( DKK22.47 ) 2024-07-31 |
Last Dividend | DKK0 ( N/A ) |
Next Dividend | DKK0 ( N/A ) |
P/E | 24.09 |
ATR14 | DKK2.69 (0.13%) |
音量 相关性
Genmab A/S 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Genmab A/S 相关性 - 货币/商品
Genmab A/S 财务报表
Annual | 2023 |
营收: | DKK16.47B |
毛利润: | DKK16.25B (98.63 %) |
EPS: | DKK66.64 |
FY | 2023 |
营收: | DKK16.47B |
毛利润: | DKK16.25B (98.63 %) |
EPS: | DKK66.64 |
FY | 2022 |
营收: | DKK14.60B |
毛利润: | DKK14.60B (100.00 %) |
EPS: | DKK83.38 |
FY | 2021 |
营收: | DKK8.48B |
毛利润: | DKK0.00 (0.00 %) |
EPS: | DKK46.00 |
Financial Reports:
No articles found.
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。